MPL Exon 10 Mutation Detection, Reflex, Varies
Use
This test aids in the distinction between reactive cytosis and chronic myeloproliferative disorders. It evaluates for mutations in MPL as part of an algorithmic process for diagnosing BCR::ABL1-negative myeloproliferative neoplasms (MPN) alongside JAK2 V617F and CALR mutations. Identifying mutations in MPL exon 10 is useful for diagnosing certain MPN subtypes, as MPL exon 10 variants are observed in 5%-10% of primary myelofibrosis and 3%-5% of essential thrombocythemia cases.
Special Instructions
This test is only orderable as a reflex and is part of a broader algorithm including JAK2 V617F and CALR mutation testing. For ordering, refer to the MPNR test encompassing JAK2 V617F with reflex to CALR and MPL mutations.
Limitations
A positive result does not specify a particular myeloproliferative neoplasm subtype; clinical correlation is necessary. Negative results do not rule out the presence of an MPN or other neoplasms. Rare variants outside of MPL exon 10 or interfering with PCR primers may lead to false negatives.
New York Approved
Methodology
Sanger
Biomarkers
LOINC Codes
- 62948-5
- 22637-3
Result Turnaround Time
7-10 days
Related Documents
For more information, please review the documents below
Specimen
Other
Volume
Not provided
Minimum Volume
Not provided
Collection Instructions
Only orderable as a reflex; see MPNR test details.
Causes for Rejection
Gross hemolysis; paraffin embedded bone marrow aspirate clot or biopsy blocks; slides; paraffin shavings; moderately to severely clotted